- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04223895
A Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-386 in Healthy Adult Volunteers
Phase I Clinical Trial to Compare the Pharmacokinetics and Tolerability of CKD-386 With Co-administration of D012, D326, and D337 in Healthy Adult Volunteers
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Tipo de estudo
Inscrição (Antecipado)
Estágio
- Fase 1
Contactos e Locais
Contato de estudo
- Nome: Jae Ri Bae
- Número de telefone: 82-2-2194-0468
- E-mail: jaeri@ckdpharm.com
Estude backup de contato
- Nome: Yook-Hwan Noh
- Número de telefone: 82-70-4665-9174
- E-mail: yook.noh@gmail.com
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Those who are over 19 years old at the screening visit
- Those who weigh more than 50kg (45kg or more for women) at the screening visit and have a body mass index (BMI) within the range of 18-30kg/m^2
Those who meet the following conditions of blood pressure measured in a sitting position after sufficient rest at the screening visit
- Systolic blood pressure: 90mmHg or more and 139mmHg or less
- Diastolic blood pressure: 60mmHg or more and 89mmHg or less
- Those who no congenital or chronic disease based on screening and no pathological symptoms or findings in medical examination results (e.g. EEG, ECG, chest and gastroscopy or gastrointestinal radiographs, if necessary)
- The person in charge of the examination (or authorized test physician) who has determined that the test subject is suitable for the diagnostic test and electrocardiogram test such as hematology test, blood chemistry test, serology test and urine test performed according to the characteristics of the investigational drug product
- Persons agreeing to exclude the possibility of pregnancy using appropriate contraceptive methods and not providing sperm or eggs from the date of first administration of the investigational drug to the 14th day after the last administration of the investigational drug
Exclusion Criteria:
- Those who participated in other clinical trials (including bioequivalence studies) within 6 months before the first dose and received the investigational drug
- Those who used drugs that induce and inhibit metabolic enzymes, such as barbital drugs, within one month before the first dose, or who used drugs that may interfere with this test within 10 days before the first dose
- Those who have donated whole blood within 2 months before the first dose or component donation within 1 month, or have transfused within 1 month
- Those who have had a history of gastrointestinal resection that may affect the absorption of the investigational drug (except appendectomy and hernia surgery)
A person who meets the following conditions within one month before the first administration date
Excess alcohol: 21 cups / week for men and 14 cups / week for women.
[1 glass = 50 mL of shochu or 30 mL of liquor or 250 mL of beer]
- Smokers exceeding 20 cigarettes per day
Patients with the following diseases
- Patients with hypersensitivity to the main constituents or components of the investigational drug
- Severe hepatic impairment, biliary atresia or cholestasis
- Patients with hereditary angioedema or with a history of angioedema in the treatment of ACE inhibitors or angiotensin II receptor antagonists
- Diabetes mellitus
- Patients with moderate to severe renal impairment [glomerular filtration rate (eGFR) <60 mL / min / 1.73m^2]
- Renal vascular hypertension patients
- Patients with active liver disease, including unexplained persistent serum transaminase elevations or elevated serum transaminase elevations greater than three times the normal upper limit
- Patients with myopathy or have a history of family or genetic history of myopathy
- Hypothyroidism
- If you have a history of muscle toxicity for other HMG-CoA converting enzymes or fibrate class drugs
- Genetic problems such as galactose intolerance, Lapp lactose deficiency, or glucose-galactose malabsorption
- person who is considered to be unsuitable for participation in this clinical trial for reasons other than the above selection / exclusion criteria.
- In the case of female volunteers, the suspected or lactating woman
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição cruzada
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Group 1
Period 1: D012, D326, D337(3 tabs, once) / Period 2: CKD-386 F1(1 tab, once)/ Period 3: CKD-386 F2(1 tab, once)
|
A single oral dose of 1 tablet under fasting conditions for each period
Outros nomes:
A single oral dose of 1 tablet under fasting conditions for each period
Outros nomes:
A single oral dose of 3 tablets(D012, D326 and D337) under fasting conditions for each period
|
Experimental: Group 2
Period 1: D012, D326, D337(3 tabs, once) / Period 2: CKD-386 F2(1 tab, once)/ Period 3: CKD-386 F1(1 tab, once)
|
A single oral dose of 1 tablet under fasting conditions for each period
Outros nomes:
A single oral dose of 1 tablet under fasting conditions for each period
Outros nomes:
A single oral dose of 3 tablets(D012, D326 and D337) under fasting conditions for each period
|
Experimental: Group 3
Period 1: CKD-386 F1(1 tab, once) / Period 2: D012, D326, D337(3 tabs, once) Period 3: CKD-386 F2(1 tab, once)
|
A single oral dose of 1 tablet under fasting conditions for each period
Outros nomes:
A single oral dose of 1 tablet under fasting conditions for each period
Outros nomes:
A single oral dose of 3 tablets(D012, D326 and D337) under fasting conditions for each period
|
Experimental: Group 4
Period 1: CKD-386 F1(1 tab, once) / Period 2: CKD-386 F2(1 tab, once) / Period 3: D012, D326, D337(3 tabs, once)
|
A single oral dose of 1 tablet under fasting conditions for each period
Outros nomes:
A single oral dose of 1 tablet under fasting conditions for each period
Outros nomes:
A single oral dose of 3 tablets(D012, D326 and D337) under fasting conditions for each period
|
Experimental: Group 5
Period 1: CKD-386 F2(1 tab, once) / Period 2: D012, D326, D337(3 tabs, once)/ Period 3: CKD-386 F1(1 tab, once)
|
A single oral dose of 1 tablet under fasting conditions for each period
Outros nomes:
A single oral dose of 1 tablet under fasting conditions for each period
Outros nomes:
A single oral dose of 3 tablets(D012, D326 and D337) under fasting conditions for each period
|
Experimental: Group 6
Period 1: CKD-386 F2(1 tab, once) / Period 2: CKD-386 F1(1 tab, once) / Period 3: D012, D326, D337(3 tabs, once)
|
A single oral dose of 1 tablet under fasting conditions for each period
Outros nomes:
A single oral dose of 1 tablet under fasting conditions for each period
Outros nomes:
A single oral dose of 3 tablets(D012, D326 and D337) under fasting conditions for each period
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
AUCt of each main component or metabolite of the component after single dose of CKD-386 F1, CKD-386 F2 and D012, D326, D337
Prazo: 0(predose)~72 hours
|
AUCt: Area under the concentration-time curve
|
0(predose)~72 hours
|
Cmax of each main component or metabolite of the component after single dose of CKD-386 F1, CKD-386 F2 and D012, D326, D337
Prazo: 0(predose)~72 hours
|
Cmax: Maximum plasma concentration of the drug
|
0(predose)~72 hours
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
AUCinf each main component or the metabolite of the component after single dose of CKD-386 F1, CKD-386 F2 and D012, D326, D337
Prazo: 0(predose)~72 hours
|
AUCinf: Area under the concentration-time curve from zero up to ∞
|
0(predose)~72 hours
|
tmax each main component or the metabolite of the component after single dose of CKD-386 F1, CKD-386 F2 and D012, D326, D337
Prazo: 0(predose)~72 hours
|
tmax: Time to maximum plasma concentration
|
0(predose)~72 hours
|
AUCt/AUCinf each main component or the metabolite of the component after single dose of CKD-386 F1, CKD-386 F2 and D012, D326, D337
Prazo: 0(predose)~72 hours
|
AUCt/AUCinf: AUCt/AUCinf Ratio
|
0(predose)~72 hours
|
t1/2 each main component or the metabolite of the component after single dose of CKD-386 F1, CKD-386 F2 and D012, D326, D337
Prazo: 0(predose)~72 hours
|
t1/2: Terminal elimination half-life
|
0(predose)~72 hours
|
AUCt of each main component or metabolite of the component after single dose of CKD-386 F1, CKD-386 F2 and D326, D337
Prazo: 0(predose)~72 hours
|
AUCt: Area under the concentration-time curve
|
0(predose)~72 hours
|
Cmax of each main component or metabolite of the component after single dose of CKD-386 F1, CKD-386 F2 and D326, D337
Prazo: 0(predose)~72 hours
|
Cmax: Maximum plasma concentration of the drug
|
0(predose)~72 hours
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: 70-4665-9174 70-4665-9174, H plus Yangji Hospital
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Antecipado)
Conclusão Primária (Antecipado)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- A83_04BE1917P
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em CKD-386 Formulation 1
-
Chong Kun Dang PharmaceuticalDesconhecidoHipertensão | DislipidemiasRepublica da Coréia
-
Chong Kun Dang PharmaceuticalConcluídoHipertensão e DislipidemiaRepublica da Coréia
-
Chong Kun Dang PharmaceuticalConcluídoHipertensão e DislipidemiaRepublica da Coréia
-
Chong Kun Dang PharmaceuticalConcluídoHipertensão e DislipidemiaRepublica da Coréia
-
Chong Kun Dang PharmaceuticalConcluídoHipertensão e DislipidemiaRepublica da Coréia
-
Chong Kun Dang PharmaceuticalConcluídoHipertensão e DislipidemiaRepublica da Coréia
-
Chong Kun Dang PharmaceuticalConcluídoHipertensão e DislipidemiaRepublica da Coréia
-
Chong Kun Dang PharmaceuticalDesconhecido
-
Chong Kun Dang PharmaceuticalRecrutamentoAlopecia AndrogenéticaRepublica da Coréia
-
Chong Kun Dang PharmaceuticalConcluídoHipertensãoRepublica da Coréia